¡¶ÃÀÉÙÅ®ÌØ¹¤¶Ó¡·10²¿ÌØÊâ¾çÇéӰƬ"/> ¼ÇÕß:ʯÏþµ¤ ±à¼­:º«è´Ó¨ У¶Ô:ÑîºÉ·Å"/>

ÌÚ²©tengbo9885¹ÙÍø

¡¶ÃÀÉÙÅ®ÌØ¹¤¶Ó¡·10²¿ÌØÊâ¾çÇéӰƬ

¡¶ÃÀÉÙÅ®ÌØ¹¤¶Ó¡·10²¿ÌØÊâ¾çÇéӰƬ

¡¶¡¶ÃÀÉÙÅ®ÌØ¹¤¶Ó¡·10²¿ÌØÊâ¾çÇéӰƬ¡·¾çÇé¼ò½é£º¼ÇÕß:ʯÏþµ¤ ±à¼­:º«è´Ó¨ У¶Ô:ÑîºÉ·ÅÕÐÄý×¹ÔÚºóÃæ¿´×ÅÒ»ÍûÎ޼ʵĸ߲Ýè­è²Ðdz½ÏÂ΢·ç·÷¹ýÏñÀËÓ¿¶¯Ó©»ðÐÇÐǵãµãµÄÆ®ÆðÓÖËæ×Å·çÎ趯¾ÍÏñÊǺ£ÉÏµÄ¹â´ø¡¶ÃÀÉÙÅ®ÌØ¹¤¶Ó¡·10²¿ÌØÊâ¾çÇéӰƬÏÖÔÚÁ½ÈËÈ«ÉíѪɫ¹âÏßÁ÷¶¯Ò»¹É¹ÉǿʢµÄÆøÁ÷±¼Ó¿³öÀ´Ç¡ËÆÒ»ÕóÕó¿ñ·çÂÓ¹ýµØÃæÄÇǿʢµÄÆøÁ÷¹¥»÷ÕðµÄµØÃæ»Ò³¾±©Ó¿Äü¶ñµÄÉñÁ¦Õðµ´Ö®ÏµØÃ澹Ȼ·ºÆðÁËÒ»µÀµÀ¹êÁѵĺۼ£SMART-CHOICE 3 investigators. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial. Lancet. 2025 Mar 28:S0140-6736(25)00449-0.

¡¶¡¶ÃÀÉÙÅ®ÌØ¹¤¶Ó¡·10²¿ÌØÊâ¾çÇéӰƬ¡·ÊÓÆµËµÃ÷£ºÄÇѪÅè´ó¿ÚÖ®ÖеÄÉ­É­¶¾ÑÀºÍÏóÑÀÒ»Ñùƽ³£³¤¼âÈñÎޱȿɼû±»Ò§µ½Á˸ÃÊǸöʲôϳ¡·½º®ÖªµÀÕâºÚË®ÍõÉßµÄâ²ÑÀ±ÈÆðÐÞÂ޹Ǵ̶¼ºÃÉÏÊ®±¶ÈôÊDZ»ÌìÈ˾³µÄÄÜÊÖ»ñµÃÖ®ºó´òÈëÖÖÖÖ´óÕóÓ÷¨Á¦Ï´Á·ÉõÖÁ¿ÉÒÔÁ¶ÖƳɱ¦Æ÷¼¶±ðµÄ·É½£¸ßŮʿ¶¼¶Ô×Ô¼ºÎÞÓïÁËËý×Ô¼º¾ÍÊǺܼ±ÔêµÄÐÔ¸ñ×Ô´Ó»ÙÈÝÁËÖ®ºóÍøÂçÉÏ»òÊÇÃÀÈÝԺ˵Óв½·¥ÐÞ¸´×Ô¼ºµÄÁ³×Ô¼º¾ÍÈ¥×öÖÖÖÖʵÑéĨҩ¸à¡¢×ö¹öÕë¡¢ÉõÖÁ»¹È¥×öËùνµÄÅÅѪ»»À´µÄÈ´ÊÇÁ³²¿×´Ì¬Ô½À´Ô½²î״ʦÒÔΪ±¾°¸¹Øºõ»¥ÁªÍøµÄδÀ´ÒÔ¼°¹È¸èµÄËÑË÷ÒýÇæ»á²»ÅöÃæÁÙʵÖÊÐԵľºÕùÖ¤¾Ý½«Ö¤Êµ¹È¸èÒÑÍùÒªÇóÇ©ÊðÓйØÄ¬ÈÏËÑË÷ÒýÇæµÄÅÅËûÐÔЭÒé×èÖ¹ÆäËûµÐÊÖÔÚËÑË÷ÁìÓòµÄ¾ºÕù

±à¾ç£º
¸üУº

2025-09-18 10:14:26

±¸×¢£º
¹úÓï
ÆÀ¼Û£º
¡¶ÃÀÉÙÅ®ÌØ¹¤¶Ó¡·10²¿ÌØÊâ¾çÇéӰƬ
Ê×Ò³
Ó°Ï·
Ò»Á¬¾ç
×ÛÒÕ
¶¯Âþ
APP
ÍøÕ¾µØÍ¼